Are There Any Clinical Studies Supporting Follistatin as a Hair Loss Treatment?

Hair loss is a complex and emotionally charged issue, and emerging compounds like follistatin draw a lot of attention. Promoted in online forums and supplement stores as a potential hair regrowth solution, follistatin has a following — but how much of that enthusiasm is backed by clinical science? Answering that means looking at what follistatin does, what has actually been published about it, and whether any of it amounts to evidence for treating hair loss.

What Exactly Is Follistatin, and Why Are People Linking It to Hair Growth?

Follistatin is a protein that occurs naturally in the body. Its main role is to regulate members of the transforming growth factor-beta (TGF-β) family, which includes proteins like activin and myostatin. These proteins are involved in many biological processes, including cell growth, inflammation, and tissue repair. Follistatin binds to activin and neutralizes its effects. In skin biology, activin has been described as able to inhibit follicular development, so blocking it might in theory encourage the hair follicle to stay longer in its growth phase, known as the anagen phase.

That is the logic. Logic alone is not evidence. The question is whether serious, verifiable research in humans supports the theory.

Does the Research Actually Back It Up?

Despite the online interest, published research on follistatin as a hair loss treatment is scarce — and in humans, close to nonexistent. What exists is mostly in mice, in cultured cells, or in isolated skin. Studies of that kind are normal in early-stage research, but they do not establish that something works as a treatment.

The strongest genuinely published work in this area is basic biology rather than treatment testing. A 2003 study in the FASEB Journal by Nakamura and colleagues examined how follistatin and activin interact to control the development and cycling of mouse pelage hair follicles, using genetically modified mice. It is the paper most often behind the claim that follistatin influences the hair cycle. It is a mouse developmental study, not a test of follistatin as a hair-loss treatment, and mouse skin and hair cycles differ substantially from human scalp. A 2008 review in Cytokine & Growth Factor Reviews by McDowall and colleagues surveys what is known about activins and follistatins in skin and hair follicle development and function, and it too describes a signalling system rather than a therapy.

Several other follistatin hair studies circulate online that could not be found in PubMed — including a 2012 mouse gene-therapy paper attributed to Molecular Therapy*, a 2014 dermal papilla paper attributed to the* Journal of Investigative Dermatology*, and a 2018 ex vivo human skin experiment attributed to* Experimental Dermatology*. Because their existence could not be confirmed, none of their results are described here.*

The one human study of follistatin for hair that can be verified is a first-in-man phase 1 trial by Zimber and colleagues, published in the Journal of Drugs in Dermatology in 2011. It gave 26 men with androgenetic alopecia, at a single site and in a trial run by the product's maker (Histogen), a single intradermal injection of a cell-derived preparation containing Wnt proteins and follistatin, and reported small increases over placebo in hair shaft thickness and terminal hair density at 12 weeks. A phase 1 trial is small, short and designed mainly to look at safety; it also tested a combination product, so it cannot show what follistatin on its own does. No larger controlled trial has followed it.

Is Follistatin Approved or Regulated by Health Authorities?

No. Follistatin is not approved by the U.S. Food and Drug Administration for any use related to hair loss or hair growth. Most human research involving follistatin has concerned muscle-wasting conditions. Those trials generate safety data about follistatin gene therapy in that setting, but they do not measure or report hair growth outcomes.

An example is the trial registered as NCT01519349, "Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis", now listed as completed on ClinicalTrials.gov. Its aim was muscle mass, not hair. It says nothing about follistatin's effect on hair follicles.

What About Supplements or Topical Follistatin?

Many products claim to contain follistatin or to raise its levels naturally. These include pills, creams, and injectable peptides. There is no published, peer-reviewed evidence that topical or oral follistatin products reach the hair follicle or produce visible regrowth. Follistatin is a protein, and proteins are generally broken down in the digestive system before they can enter the bloodstream. Topical delivery faces the same obstacle from the other direction, as proteins of this size have difficulty crossing the skin barrier without a specialised delivery system.

The FDA also does not regulate supplements the way it regulates drugs. A company can sell a follistatin supplement without demonstrating that it works or that it is safe, which leaves buyers exposed to unsupported advertising claims. Injectable products sold outside a clinical trial are unregulated, their contents are unverified, and their safety is unknown.

So, Where Do We Stand? Is Follistatin a Real Option for Hair Loss?

On the published evidence, follistatin is an experimental compound for hair loss, not a treatment. Its proposed rationale is blocking activin to prolong the anagen phase. Animal and laboratory work does show that follistatin and activin affect hair follicle development, but the direction is not settled: in the Nakamura mouse study, mice with extra activin actually entered the regression phase later. What is missing is human trial evidence measuring hair growth: one small phase 1 injection study of a combination product is the whole of it, so follistatin cannot be described as a credible option at this time.

Anyone considering follistatin for hair loss should understand that the available knowledge is preliminary, fragmented, and largely confined to laboratory settings. Until controlled trials in humans are run and published, this is a hypothesis rather than a therapy, and its long-term safety in this use is unknown.

Talk to a doctor or pharmacist before starting, stopping or combining any hair-loss treatment, and before taking or injecting any unapproved compound such as follistatin.

References

Nakamura, M., Matzuk, M. M., Gerstmayer, B., Bosio, A., Lauster, R., Miyachi, Y., Werner, S., & Paus, R. (2003). Control of pelage hair follicle development and cycling by complex interactions between follistatin and activin. FASEB Journal, 17(3), 497–499. PMID: 12514121. https://pubmed.ncbi.nlm.nih.gov/12514121/

McDowall, M., Edwards, N. M., Jahoda, C. A. B., & Hynd, P. I. (2008). The role of activins and follistatins in skin and hair follicle development and function. Cytokine & Growth Factor Reviews, 19(5–6), 415–426. PMID: 18922734. https://pubmed.ncbi.nlm.nih.gov/18922734/

Zimber, M. P., Ziering, C., Zeigler, F., Hubka, M., & Mansbridge, J. N. (2011). Hair regrowth following a Wnt- and follistatin containing treatment: safety and efficacy in a first-in-man phase 1 clinical trial. Journal of Drugs in Dermatology, 10(11), 1308–1312. PMID: 22052313. https://pubmed.ncbi.nlm.nih.gov/22052313/

U.S. National Library of Medicine. (n.d.). Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis. ClinicalTrials.gov Identifier: NCT01519349. https://clinicaltrials.gov/study/NCT01519349